Yunnan Center for Disease Control and Prevention, Yunnan, China.
Wenshan Institute of Dermatology, Wenshan Dermatology Hospital, The Alliance Hospital of the First Affiliated Hospital of Kunming Medical University, Yunnan, China.
PLoS Negl Trop Dis. 2021 Mar 16;15(3):e0009201. doi: 10.1371/journal.pntd.0009201. eCollection 2021 Mar.
This study reviews the progress of leprosy elimination in Yunnan, China, over the past 30 years and identifies the challenges for the next stage of the program.
METHODOLOGY/PRINCIPAL FINDINGS: Data were collected from the Leprosy Management Information System in China (LEPMIS). The progress made in the elimination of leprosy between 1990 and 2019 was measured. We defined two time periods, time period 1 (1990-2003) and time period 2 (2004-2019), because multidrug therapy (MDT) was launched for the treatment of leprosy in 1990 and a special fund from the central government was established for leprosy in 2004. During the past 30 years, the number of newly detected leprosy patients in Yunnan has steadily declined. In total, 703 newly detected leprosy patients were reported in 1990, and 353 and 136 cases were reported at the end of 2003 and 2019, respectively. At the end of 1990, 90.7% (117/129) of counties in Yunnan Province were identified as leprosy-endemic counties (>1 case per 100,000 population). By the end of 2003 and 2019, 39.3% (46/117) and 85.5% (100/117) of the leprosy-endemic counties, respectively, had dropped below the elimination threshold. The main challenges are the remaining leprosy-endemic counties, the high rate of cases with a contact history, insufficient early detection, and leprosy cases resulting in physical disability.
CONCLUSIONS/SIGNIFICANCE: A multifaceted strategy for leprosy elimination in Yunnan Province has been successfully implemented, and remarkable progress has been made in the elimination of leprosy in this area. The priorities for leprosy elimination in the next stage are securing sustainable support and investment from the government, establishing an effective surveillance system, ensuring prompt early detection, providing treatment with MDT, preventing transmission of M. leprae, preventing disability, providing health education, and preventing recurrence of the epidemic situation of leprosy.
本研究回顾了过去 30 年来中国云南省麻风病消除工作的进展,并确定了下一阶段计划的挑战。
方法/主要发现:数据来自中国麻风病管理信息系统(LEPMIS)。衡量了 1990 年至 2019 年期间消除麻风病的进展。我们定义了两个时间段,时间段 1(1990-2003 年)和时间段 2(2004-2019 年),因为 1990 年开始采用多药疗法(MDT)治疗麻风病,中央政府于 2004 年为麻风病设立了专项基金。在过去的 30 年中,云南省新发现的麻风病患者数量稳步下降。1990 年共报告新发现麻风病患者 703 例,2003 年底和 2019 年底分别报告 353 例和 136 例。1990 年底,云南省 90.7%(117/129)的县被认定为麻风病流行县(>10 万人口中有 1 例以上)。到 2003 年底和 2019 年底,分别有 39.3%(46/117)和 85.5%(100/117)的流行县下降到消除阈值以下。主要挑战是剩余的麻风病流行县、有接触史的病例比例高、早期发现不足以及麻风病导致身体残疾的病例。
结论/意义:云南省麻风病消除的多方面战略已成功实施,该地区麻风病消除工作取得了显著进展。下一阶段麻风病消除的重点是确保政府持续提供支持和投资,建立有效的监测系统,确保及时早期发现,提供 MDT 治疗,预防麻风分枝杆菌传播,预防残疾,开展健康教育,防止麻风病疫情复发。